Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average rating of “Buy” from the sixteen analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $48.79.

HOLX has been the subject of a number of research analyst reports. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Saturday. Evercore ISI initiated coverage on shares of Hologic in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 target price for the company. Cowen raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price for the company in a research note on Monday, December 11th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st.

Hologic (NASDAQ:HOLX) opened at $43.71 on Tuesday. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The stock has a market cap of $12,050.13, a price-to-earnings ratio of 16.56, a PEG ratio of 2.09 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter in the previous year, the business earned $0.52 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. sell-side analysts expect that Hologic will post 2.15 earnings per share for the current fiscal year.

In other Hologic news, VP Karleen Marie Oberton sold 1,256 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the sale, the vice president now directly owns 9,406 shares of the company’s stock, valued at approximately $369,561.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders have sold a total of 12,099 shares of company stock worth $487,223 over the last three months. Insiders own 0.79% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after purchasing an additional 1,200,825 shares during the period. Parnassus Investments CA bought a new stake in shares of Hologic in the 3rd quarter valued at about $277,062,000. Capital World Investors bought a new stake in shares of Hologic in the 2nd quarter valued at about $312,441,000. Victory Capital Management Inc. raised its holdings in shares of Hologic by 16.8% in the 3rd quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock valued at $214,885,000 after purchasing an additional 844,426 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Hologic by 2.5% in the 2nd quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock valued at $148,743,000 after purchasing an additional 79,697 shares during the period. 97.58% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Receives Average Rating of “Buy” from Analysts” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/01/16/hologic-inc-holx-receives-average-rating-of-buy-from-analysts.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.